Validation Study of a New Digital Treatment Test
Primary Purpose
Alzheimer Disease, MCI
Status
Unknown status
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
BGaze therapy Alzheimer
Sponsored by
About this trial
This is an interventional treatment trial for Alzheimer Disease
Eligibility Criteria
Inclusion Criteria:
1) Clinical diagnosis of MCI or AD
Exclusion Criteria:
- Severe cognitive deterioration
- History of neurological disease with clinically relevant impact on cognition
- Severe psychiatric disorder
- Incidental structural brain findings with impact on cognitive impairment
- Presence of relevant visual problems
Sites / Locations
- BraingazeRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Treatment
Arm Description
Outcomes
Primary Outcome Measures
MoCA
Measure changes in MoCA
MMSE
Measure changes in MMSE
Secondary Outcome Measures
CANTAB
Measure changes in CANTAB tests
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04897464
Brief Title
Validation Study of a New Digital Treatment Test
Official Title
Validation Study of a New Digital Treatment Test Based on Interactive Video Games for Alzheimer's Disease
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Unknown status
Study Start Date
June 1, 2021 (Anticipated)
Primary Completion Date
March 31, 2022 (Anticipated)
Study Completion Date
May 31, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Braingaze
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Oculomotor behavior and cognitive processing of visual information are intimately connected. AD patients show ocular movement problems. Oculomotor deficits are broad consisting mainly of different saccade metrics, altered pupil responses. and smaller and irregular eye vergence movements. Here we test an interactive eye-tracking game to improve eye motion control and thereby training cognitive behavior
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease, MCI
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Treatment
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
BGaze therapy Alzheimer
Intervention Description
BGaze Therapy is an interactive eye tracking game
Primary Outcome Measure Information:
Title
MoCA
Description
Measure changes in MoCA
Time Frame
immediately after the intervention
Title
MMSE
Description
Measure changes in MMSE
Time Frame
immediately after the intervention
Secondary Outcome Measure Information:
Title
CANTAB
Description
Measure changes in CANTAB tests
Time Frame
immediately after the intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
1) Clinical diagnosis of MCI or AD
Exclusion Criteria:
Severe cognitive deterioration
History of neurological disease with clinically relevant impact on cognition
Severe psychiatric disorder
Incidental structural brain findings with impact on cognitive impairment
Presence of relevant visual problems
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hans Super
Phone
0034931696572
Email
hans@braingaze.eu
First Name & Middle Initial & Last Name or Official Title & Degree
Laszlo Bax
Phone
0034931696572
Email
Laszlo@braingaze.eu
Facility Information:
Facility Name
Braingaze
City
Mataró
State/Province
Barcelona
ZIP/Postal Code
08302
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hans Super
Email
hans@braingaze.eu
12. IPD Sharing Statement
Plan to Share IPD
Undecided
IPD Sharing Plan Description
anonymized data can be shared upon request
Learn more about this trial
Validation Study of a New Digital Treatment Test
We'll reach out to this number within 24 hrs